Omeros Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
$0.38next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 11 Nov 2026 |
Monitoring Framework
Key Performance Indicators
YARTEMLEA Net Product Sales Quarterly9.9MTarget: Self-sustaining product line in 2026
Cash and Short-Term Investments Quarterly135.3MTarget: Maintain sufficient runway to support commercial launch and pipeline development
Total Operating Expenses Quarterly27.3MTarget: Controlled spending post-Novo Nordisk transaction
Watch Items
- EMA Marketing Authorization Application (MAA) Decision for YARTEMLEATrigger: Mid-2026 decision windowAction: Prepare European commercialization strategy or secure ex-U.S. partnerships upon approval
- CMS New Technology Add-On Payment (NTAP) Final DecisionTrigger: August 2026 decision windowAction: Optimize inpatient reimbursement and hospital formulary access starting October 1, 2026
- Non-cash mark-to-market adjustments on 2029 convertible notes embedded derivativesTrigger: High volatility in GAAP net income/loss based on stock price fluctuationsAction: Focus on non-GAAP adjusted net loss to evaluate underlying operational performance
Research as of 19 Jun 2026